IP Library Granted Patent US 12,269,802
Granted Patent B2
US 12,269,802 · App. 18/334,101 · Granted Apr 8, 2025

Process for preparing 2-[[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl] amino] acetic acid

Inventors: Boris I. Gorin (Oakville, CA); Christopher M. Lanthier (Burlington, CA); Anne Buu Chau Luong (Mississauga, CA); James Densmore Copp (Bargersville, IN); Javier Gonzalez (Lafayette, IN); Sascha Jautze (Piscataway, NJ); Erich Kraus (Essen, DE); Alan O'Connor (Piscataway, NJ)
Assignee: Akebia Therapeutics, Inc.
C07D213/81
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,269,802
App. No.
18/334,101
Granted
Apr 8, 2025
Kind
B2
Abstract

Disclosed herein are methods and processes of preparing vadadustat and pharmaceutically acceptable salts thereof, and intermediates of formula (I) and their salts useful for the synthesis of vadadustat.

Claims (30)

1. A compound of Formula (I):

or a salt thereof, wherein:

R 1 is C 1-4 alkyl, CH 2 Cl, phenyl, or benzyl, in which each of phenyl and benzyl may be independently substituted with one, two or three substituents selected from methyl, methoxy, nitro and halogen; and

R 2 is C 1-4 alkyl; and

wherein the compound comprises less than about 0.5% of the compound of Formula (5):

2. The compound of claim 1 or a salt thereof, wherein R 1 is t-butyl and/or R 2 is methyl.

3. The compound of claim 1 or a salt thereof, which is at least about 80% pure, about 85% pure, about 90% pure, or about 95% pure.

4. The compound of claim 1 or a salt thereof, wherein the compound comprises less than about 0.3% of the compound of Formula (5).

5. The compound of claim 1 or a salt thereof, wherein the compound comprises less than about 0.2% of the compound of Formula (5).

6. The compound of claim 1 or a salt thereof, wherein the compound comprises less than about 0.1% of the compound of Formula (5).

7. The compound of claim 1 or a salt thereof, wherein the compound comprises less than about 0.05% of the compound of Formula (5).

8. The compound of claim 1 or a salt thereof, wherein the compound of Formula (I) is isolated.

9. A composition comprising:

a) 80% or more of a compound of Formula (I) or a salt thereof,

wherein:

R 1 is C 1-4 alkyl, CH 2 Cl, phenyl, or benzyl, in which each of phenyl and benzyl may be independently substituted with one, two or three substituents selected from methyl, methoxy, nitro and halogen;

R 2 is C 1-4 alkyl; and

b) 20% or less of a compound of Formula (IV) or a salt thereof,

wherein R 2 is C 1-4 alkyl;

wherein the composition comprises less than about 0.5% of the compound of Formula (5):

and

wherein the combined amount of the compound of Formula (I), or a salt thereof, and the compound of Formula (IV), or a salt thereof, is between about 99% and about 100% of the composition.

10. The composition of claim 9 , wherein R 1 is t-butyl and or R 2 is methyl.

11. The composition of claim 9 , comprising 85% or more of the compound of Formula (I), or a salt thereof, and 15% or less of the compound of Formula (IV), or a salt thereof.

12. The composition of claim 9 , comprising 90% or more of the compound of Formula (I), or a salt thereof, and 10% or less of the compound of Formula (IV), or a salt thereof.

13. The composition of claim 9 , comprising less than about 0.3% of the compound of Formula (5).

14. The composition of claim 9 , comprising less than about 0.2% of the compound of Formula (5).

15. The composition of claim 9 , comprising less than about 0.1% of the compound of Formula (5).

16. The composition of claim 9 , comprising less than about 0.05% of the compound of Formula (5).

17. The compound of claim 3 , wherein purity is as measured by HPLC.

Assignments (7)
SECURITY INTEREST Recorded Jan 29, 2024
From: AKEBIA THERAPEUTICS, INC.; KERYX BIOPHARMACEUTICALS, INC.
To: KREOS CAPITAL VII (UK) LIMITED
Reel/Frame 066377/0654 →
CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNOR NAME PREVIOUSLY RECORDED AT REEL: 063995 FRAME: 0625. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Jun 27, 2023
From: EVONIK OPERATIONS GMBH
To: EVONIK CORPORATION
Reel/Frame 064121/0893 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 20, 2023
From: JAUTZE, SASCHA; O'CONNOR, ALAN
To: EVONIK CORPORATION
Reel/Frame 063995/0550 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 20, 2023
From: GORIN, BORIS I.; LUONG, ANNE BUU CHAU; COPP, JAMES DENSMORE; GONZALEZ, JAVIER; LANTHIER, CHRISTOPHER M.
To: AKEBIA THERAPEUTICS, INC.
Reel/Frame 063995/0303 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 20, 2023
From: EVONIK CORPORATION
To: AKEBIA THERAPEUTICS, INC.
Reel/Frame 063995/0702 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 20, 2023
From: EVONIK CORPORATION GMBH
To: EVONIK CORPORATION
Reel/Frame 063995/0625 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 20, 2023
From: KRAUS, ERICH
To: EVONIK OPERATIONS GMBH
Reel/Frame 063995/0396 →
Continuity (3)
Division 17053614
Provisional Application 62669135 · May 9, 2018
Related Publication 20240158354A1 · May 16, 2024
References Cited (323)
US 3655679A · Shen et al. · 1972 [cited by applicant]
US 3703582A · Shen et al. · 1972 [cited by applicant]
US 3894920A · Kondo et al. · 1975 [cited by applicant]
US 4016287A · Eberhardt et al. · 1977 [cited by applicant]
US 5397799A · Kress et al. · 1995 [cited by applicant]
US 5405613A · Rowland · 1995 [cited by applicant]
US 5607954A · Weidmann et al. · 1997 [cited by applicant]
US 5610172A · Weidmann et al. · 1997 [cited by applicant]
US 5620995A · Weidmann et al. · 1997 [cited by applicant]
US 5620996A · Weidmann et al. · 1997 [cited by applicant]
US 5658933A · Weidmann et al. · 1997 [cited by applicant]
US 5719164A · Weidmann et al. · 1998 [cited by applicant]
US 5726305A · Weidmann et al. · 1998 [cited by applicant]
US 6020350A · Weidmann et al. · 2000 [cited by applicant]
US 6093730A · Weidmann et al. · 2000 [cited by applicant]
US 6159379A · Means et al. · 2000 [cited by applicant]
US 6420427B1 · Takahashi et al. · 2002 [cited by applicant]
US 6566088B1 · Mcknight et al. · 2003 [cited by applicant]
US 6589758B1 · Zhu · 2003 [cited by applicant]
US 7183287B2 · Durley · 2007 [cited by applicant]
US 7323475B2 · Arend et al. · 2008 [cited by applicant]
US 7588924B2 · Evdokimov et al. · 2009 [cited by applicant]
US 7811595B2 · Kawamoto et al. · 2010 [cited by applicant]
US 8050873B2 · Evdokimov et al. · 2011 [cited by applicant]
US 8124582B2 · Guenzler-Pukall et al. · 2012 [cited by applicant]
US 8129376B2 · Sundaresan et al. · 2012 [cited by applicant]
US 8273773B2 · Brameld et al. · 2012 [cited by applicant]
US 8323671B2 · Wu et al. · 2012 [cited by applicant]
US 8343952B2 · Wu et al. · 2013 [cited by applicant]
US 8512972B2 · Evdokimov et al. · 2013 [cited by applicant]
US 8530404B2 · Seeley et al. · 2013 [cited by applicant]
US 8598210B2 · Kawamoto et al. · 2013 [cited by applicant]
US 8722895B2 · Kawamoto et al. · 2014 [cited by applicant]
US 8865748B2 · Shalwitz et al. · 2014 [cited by applicant]
US 8940773B2 · Kawamoto et al. · 2015 [cited by applicant]
US 9145366B2 · Lanthier et al. · 2015 [cited by applicant]
US 9598370B2 · Kawamoto et al. · 2017 [cited by applicant]
US 9701636B2 · Copp et al. · 2017 [cited by applicant]
US 9776969B2 · Lanthier et al. · 2017 [cited by applicant]
US 9987262B2 · Copp et al. · 2018 [cited by applicant]
US 10149842B2 · Copp et al. · 2018 [cited by applicant]
US 10150734B2 · Hanselmann · 2018 [cited by examiner]
US 10246416B2 · Lanthier et al. · 2019 [cited by applicant]
US RE47437E · Kawamoto et al. · 2019 [cited by applicant]
US 10596158B2 · Copp et al. · 2020 [cited by applicant]
US 10729681B2 · Kawamoto et al. · 2020 [cited by applicant]
US 10738010B2 · Lanthier et al. · 2020 [cited by applicant]
US 11713298B2 · Gorin · 2023 [cited by examiner]
US 20020192737A1 · Kaelin et al. · 2002 [cited by applicant]
US 20030153503A1 · Klaus et al. · 2003 [cited by applicant]
US 20030176317A1 · Guenzler-Pukall et al. · 2003 [cited by applicant]
US 20040235082A1 · Fourney et al. · 2004 [cited by applicant]
US 20040254215A1 · Arend et al. · 2004 [cited by applicant]
US 20060142389A1 · Aurell et al. · 2006 [cited by applicant]
US 20060276477A1 · Klaus et al. · 2006 [cited by applicant]
US 20070105899A1 · Suzuki et al. · 2007 [cited by applicant]
US 20070154482A1 · Sukhatme et al. · 2007 [cited by applicant]
US 20070203174A1 · Klimko et al. · 2007 [cited by applicant]
US 20070213335A1 · Fitch et al. · 2007 [cited by applicant]
US 20070299086A1 · Kawamoto · 2007 [cited by applicant]
US 20080124740A1 · Evdokimov et al. · 2008 [cited by applicant]
US 20080213404A1 · Johnson et al. · 2008 [cited by applicant]
US 20090023666A1 · Gardiner et al. · 2009 [cited by applicant]
US 20090082357A1 · Fitch et al. · 2009 [cited by applicant]
US 20090240475A1 · Evdokimov et al. · 2009 [cited by applicant]
US 20100021423A1 · Brameld et al. · 2010 [cited by applicant]
US 20100331303A1 · Kawamoto et al. · 2010 [cited by applicant]
US 20100331374A1 · Wu et al. · 2010 [cited by applicant]
US 20110077400A1 · Lobben et al. · 2011 [cited by applicant]
US 20110305776A1 · Ho et al. · 2011 [cited by applicant]
US 20120282627A1 · Evdokimov et al. · 2012 [cited by applicant]
US 20120309977A1 · Lanthier et al. · 2012 [cited by applicant]
US 20120316204A1 · Shalwitz et al. · 2012 [cited by applicant]
US 20120329836A1 · Marsh et al. · 2012 [cited by applicant]
US 20130022974A1 · Chinnaiyan et al. · 2013 [cited by applicant]
US 20130203816A1 · Kawamoto et al. · 2013 [cited by applicant]
US 20130245076A1 · Kawamoto et al. · 2013 [cited by applicant]
US 20140045899A1 · Kawamoto et al. · 2014 [cited by applicant]
US 20140057892A1 · Kawamoto et al. · 2014 [cited by applicant]
US 20150119425A1 · Kawamoto et al. · 2015 [cited by applicant]
US 20150141467A1 · Copp et al. · 2015 [cited by applicant]
US 20150361043A1 · Lanthier et al. · 2015 [cited by applicant]
US 20160009648A1 · Kawamoto et al. · 2016 [cited by applicant]
US 20160143891A1 · Shalwitz et al. · 2016 [cited by applicant]
US 20160199434A1 · Eubank et al. · 2016 [cited by applicant]
US 20160214939A1 · Hanselmann et al. · 2016 [cited by applicant]
US 20160339005A1 · Shalwitz et al. · 2016 [cited by applicant]
US 20170189387A1 · Kawamoto et al. · 2017 [cited by applicant]
US 20170258773A1 · Copp et al. · 2017 [cited by applicant]
US 20170362178A1 · Lanthier et al. · 2017 [cited by applicant]
US 20180065933A1 · Hanselmann · 2018 [cited by applicant]
US 20180092892A1 · Smith et al. · 2018 [cited by applicant]
US 20180280365A1 · Copp et al. · 2018 [cited by applicant]
US 20190192494A1 · Kawamoto et al. · 2019 [cited by applicant]
US 20200345711A1 · Copp et al. · 2020 [cited by applicant]
US 20210122715A1 · Lanthier et al. · 2021 [cited by applicant]
US 20210137901A1 · Kawamoto et al. · 2021 [cited by applicant]
US 20210206721A1 · Ranjan et al. · 2021 [cited by applicant]
CA 2098158A1 · 1993 [cited by applicant]
CA 2253282A1 · 1997 [cited by applicant]
CN 105837502A · 2016 [cited by applicant]
CN 106146491A · 2016 [cited by applicant]
CN 111320577A · 2020 [cited by applicant]
EP 0650960A1 · 1995 [cited by applicant]
EP 0650961A1 · 1995 [cited by applicant]
EP 2044005B1 · 2010 [cited by applicant]
EP 3290404A1 · 2018 [cited by applicant]
EP 3290404B1 · 2019 [cited by applicant]
JP H09221476A · 1997 [cited by applicant]
JP 2001048786A · 2001 [cited by applicant]
JP 2007194072A · 2007 [cited by applicant]
JP 2010527378A · 2010 [cited by applicant]
WO 9622021A1 · 1996 [cited by applicant]
WO 9744333A1 · 1997 [cited by applicant]
WO 9741103A1 · 1997 [cited by applicant]
WO 9948870A1 · 1999 [cited by applicant]
WO 02074980A2 · 2002 [cited by applicant]
WO 02074981A2 · 2002 [cited by applicant]
WO 02083688A1 · 2002 [cited by applicant]
WO 03028663A2 · 2003 [cited by applicant]
WO 03032972A1 · 2003 [cited by applicant]
WO 03049686A2 · 2003 [cited by applicant]
WO 03053997A2 · 2003 [cited by applicant]
WO 03097040A1 · 2003 [cited by applicant]
WO 2004019868A2 · 2004 [cited by applicant]
WO 2004035812A2 · 2004 [cited by applicant]
WO 2004048383A1 · 2004 [cited by applicant]
WO 2004108121A1 · 2004 [cited by applicant]
WO 2005007192A2 · 2005 [cited by applicant]
WO 2005115984A2 · 2005 [cited by applicant]
WO 2005118836A2 · 2005 [cited by applicant]
WO 2006019831A1 · 2006 [cited by applicant]
WO 2006030977A2 · 2006 [cited by applicant]
WO 2006114213A1 · 2006 [cited by applicant]
WO 2006138511A2 · 2006 [cited by applicant]
WO 2007038571A2 · 2007 [cited by applicant]
WO 2007047194A2 · 2007 [cited by applicant]
WO 2007070359A2 · 2007 [cited by applicant]
WO 2007082899A1 · 2007 [cited by applicant]
WO 2007084667A2 · 2007 [cited by applicant]
WO 2007088571A2 · 2007 [cited by applicant]
WO 2007103905A2 · 2007 [cited by applicant]
WO 2007136990A2 · 2007 [cited by applicant]
WO 2007150011A2 · 2007 [cited by applicant]
WO 2008002576A2 · 2008 [cited by applicant]
WO 2008089051A1 · 2008 [cited by applicant]
WO 2008089052A2 · 2008 [cited by applicant]
WO 2008130508A1 · 2008 [cited by applicant]
WO 2008130527A1 · 2008 [cited by applicant]
WO 2008137060A1 · 2008 [cited by applicant]
WO 2008141731A2 · 2008 [cited by applicant]
WO 2008144266A1 · 2008 [cited by applicant]
WO 2009019656A1 · 2009 [cited by applicant]
WO 2009020119A1 · 2009 [cited by applicant]
WO 2009035534A2 · 2009 [cited by applicant]
WO 2009037570A2 · 2009 [cited by applicant]
WO 2009039321A1 · 2009 [cited by applicant]
WO 2009039323A1 · 2009 [cited by applicant]
WO 2009043093A1 · 2009 [cited by applicant]
WO 2009049112A1 · 2009 [cited by applicant]
WO 2009067790A1 · 2009 [cited by applicant]
WO 2009070644A1 · 2009 [cited by applicant]
WO 2009073497A2 · 2009 [cited by applicant]
WO 2009073669A1 · 2009 [cited by applicant]
WO 2009086044A1 · 2009 [cited by applicant]
WO 2009086592A1 · 2009 [cited by applicant]
WO 2009089547A1 · 2009 [cited by applicant]
WO 2009111337A1 · 2009 [cited by applicant]
WO 2010029577A2 · 2010 [cited by applicant]
WO 2010113942A1 · 2010 [cited by applicant]
WO 2010128355A2 · 2010 [cited by applicant]
WO 2011057112A1 · 2011 [cited by applicant]
WO 2012170377A1 · 2012 [cited by applicant]
WO 2012170439A1 · 2012 [cited by applicant]
WO 2012170442A1 · 2012 [cited by applicant]
WO 2013013609A1 · 2013 [cited by applicant]
WO 2014168986A1 · 2014 [cited by applicant]
WO 2014200773A2 · 2014 [cited by applicant]
WO 2015023967A2 · 2015 [cited by applicant]
WO 2015073779A1 · 2015 [cited by applicant]
WO 2015112831A1 · 2015 [cited by applicant]
WO 2016109300A1 · 2016 [cited by applicant]
WO 2016118858A1 · 2016 [cited by applicant]
WO 2016153996A1 · 2016 [cited by applicant]
WO 2016161094A1 · 2016 [cited by applicant]
WO 2019217550A1 · 2019 [cited by applicant]
WO 2021087144A1 · 2021 [cited by applicant]
WO 2021188936A1 · 2021 [cited by applicant]
WO 2021188938A1 · 2021 [cited by applicant]
WO 2021188944A1 · 2021 [cited by applicant]
American Diabetes Association, “Standards of Medical Care in Diabetes-2006”, Diabetes Care, vol. 29, Suppl. 1, Jan. 2006, pp. S4-S42, (39 pages). [cited by applicant]
CAS Registry Nos. 1261773-17-4, 1261723-73-2, Chemcats, 2011, (2 pages). [cited by applicant]
CAS Registry Nos. 1261813-98-2, 1261613-86-8, and 1261518-21-1, Chemcats, 2011, (2 pages). [cited by applicant]
CAS Registry Nos. 1361609-40-6, 1361556-21-9, 1361555-42-1, 1361544-77-5, 1361480- 63-8, 1361477-92-0, Chemcats, 2012, (6 pages). [cited by applicant]
CAS Registry Nos. 1361809-77-9, 1361737-20-3, 1361721-11-0, 1361693-45-9, 1361676- 79-0, Chemcats, 2012, (5 pages). [cited by applicant]
ClinicalTrials.gov, Archive No. NCT01235936, Aug. 30, 2012, retrieved Dec. 1, 2014 from URL: http://clinicaltrials.gov/archive/NCT01235936/2012_09_30, (3 pages). [cited by applicant]
Decision of the Technical Board of Appeal of the European Patent Office for Case No. T 0777/08 dated May 24, 2011, retrieved Dec. 19, 2017 from URL: https://www.epo.org/boards-of-appeal/decisions/pdf/t080777ex1.pdf (17 … [cited by applicant]
“Akebia Closes $41 Million Series C”, Triathlon Medical Ventures, Jun. 4, 2013, retrieved Dec. 1, 2014 from URL: http://www.tmvp.com/news_Akebia_06042013.html, (3 pages). [cited by applicant]
“Hippuric Acid Sodium Salt”, Science Lab.com: Chemicals & Laboratory Equipment, retrieved Mar. 11, 2010 from URL: http://web.archive.org/web/20041107121553/http://sciencelab.com/page/S/PVAR/10415/SLH2620, (1 page). [cited by applicant]
“International Preliminary Report on Patentability”, International Preliminary Report on Patentability, Ch. I, for PCT/US2019/031310 dated Nov. 19, 2020 (6 pages), Nov. 19, 2020. [cited by applicant]
“International Search Report and Written Opinion”, International Search Report and Written Opinion for PCT/US2019/031310 dated Aug. 7, 2019 (10 pages), Aug. 7, 2019. [cited by applicant]
“SCHEMBL3484399”, PubChem, National Center for Biotechnology Information, CID 49848485, Jan. 31, 2011, retrieved Mar. 15, 2016 from URL: https://pubchem.ncbi.nlm.nih.gov/compound/49848485, (13 pages). [cited by applicant]
“XEADCOHJERWFOI-UHFFFAOYSA-M”, PubChem, National Center for Biotechnology Information, CID 71491828, Jun. 10, 2013, retrieved Mar. 21, 2016 from URL: https://pubchem.ncbi.nlm.nih.gov/compound/71491828, (12 pages). [cited by applicant]
Acker, Till , et al., “Genetic evidence for a tumor suppressor role of HIF-2α”, Cancer Cell, vol. 8, No. 2, Aug. 2005, pp. 131-141, DOI: 10.1016/j.ccr.2005.07.003, (11 pages). [cited by applicant]
Alesso, Sonia M, et al., “Improving resins for solid phase synthesis: incorporation of 1-[2-(2-methoxyethoxy)ethoxy]-4-vinyl-benzene”, Tetrahedron, vol. 59, No. 36, Sep. 1, 2003, pp. 7163-7169, DOI: 10.1016/S0040-4020(0… [cited by applicant]
Altschul, Stephen F, et al., “Gapped BLAST and PSI-BLAST: a new generation of protein database search programs”, Nucleic Acids Research, vol. 25, No. 17, Sep. 1, 1997, pp. 3389-3402, DOI: 10.1093/nar/25.17.3389, (14 pag… [cited by applicant]
Anderson, Neal G, “Chapter 12—Crystallization and Purification”, Practical Process Research and Development (Second Edition), 2012, pp. 329-364, DOI: 10.1016/B978-0-12-386537-3.00012-5, (38 pages). [cited by applicant]
Anderson, Wayne K., et al., “Antileukemic activity of derivatives of 1,2-dimethyl-3,4-bis(hydroxymethyl)-5-phenylpyrrole bis(N-methylcarbamate)”, Journal of Medicinal Chemistry, vol. 22, No. 8, 1979, pp. 977-980, DOI: 1… [cited by applicant]
Annex, Brian H., et al., “Growth factor-induced therapeutic angiogenesis in the heart: protein therapy”, Cardiovascular Research, vol. 65, No. 3, Feb. 2005, pp. 649-655, DOI: 10.1016/j.cardiores.2004.09.004, (7 pages). [cited by applicant]
Ardelt, Agnieszka A., et al., “Estradiol Regulates Angiopoietin-1 mRNA Expression Through Estrogen Receptor-α in a Rodent Experimental Stroke Model”, Stroke, vol. 36, No. 2, Feb. 2005, pp. 337-341, DOI: 10.1161/01.STR.0… [cited by applicant]
Auerbach, Robert , et al., “Angiogenesis Assays: A Critical Overview”, Clinical Chemistry, vol. 49, No. 1, 2003, pp. 32-40, DOI: 10.1373/49.1.32, (9 pages). [cited by applicant]
Barany, George , et al., “Solid-phase peptide synthesis: a silver anniversary report”, Chemical Biology & Drug Design, vol. 30, No. 6, 1987, pp. 705-739, DOI: 10.1111/j.1399-3011.1987.tb03385.x, (35 pages). [cited by applicant]
Bartlett, Paul A., et al., “CAVEAT: a program to facilitate the design of organic molecules”, Molecular Recognition in Chemical and Biological Problems, Special Pub., Royal Society of Chemistry, 1989, pp. 182-196 (15 pa… [cited by applicant]
Böhm, Hans-Joachim , “The computer program LUDI: A new method for the de novo design of enzyme inhibitors”, Journal of Computer-Aided Molecular Design, vol. 6, No. 1, 1992, pp. 61-78, DOI: 10.1007/BF00124387, (18 pages). [cited by applicant]
Branden, Carl Ivar, et al., “Introduction to Protein Structure, Second Edition”, Garland Science, 1998, pp. 374-375, (4 pages). [cited by applicant]
Brittain, Harry G., et al., “Polymorphism in Pharmaceutical Solids, Second Edition”, Drugs and Pharmaceutical Sciences, vol. 192, 2009, pp. 333-335, (7 pages). [cited by applicant]
Burger, Alfred , “Isosterism and bioisosterism in drug design”, Progress in Drug Research, vol. 37, 1991, pp. 287-371, DOI: 10.1007/978-3-0348-7139-6_7, (85 pages). [cited by applicant]
Bussolino, Federico , et al., “Molecular mechanisms of blood vessel formation”, Trends in Biochemical Sciences, vol. 22, No. 7, Jul. 1997, pp. 251-256, DOI: 10.1016/s0968-0004(97)01074-8, (6 pages). [cited by applicant]
Byrn, Stephen , et al., “Pharmaceutical Solids: A Strategic Approach to Regulatory Considerations”, Pharmaceutical Research, vol. 12, No. 7, 1995, pp. 945-954, DOI: 10.1023/a:1016241927429, (10 pages). [cited by applicant]
Carey, Francis A., “”, Organic Chemistry, Sixth Edition, McGraw Hill, 2006, Chapter 1, pp. 9, Chapter 19, pp. 839-840, and Chapter 27, pp. 1182-1183, (12 pages). [cited by applicant]
Catrina, Sergiu-Bogdan , et al., “Hyperglycemia Regulates Hypoxia-Inducible Factor-1a Protein Stability and Function”, Diabetes, vol. 53, No. 12, 2004, pp. 3226-3232, DOI: 10.2337/diabetes.53.12.3226, (7 pages). [cited by applicant]
Cheeseright, Tim , “The Identification of Bioisosteres as Drug Development Candidates”, Innovations in Pharmaceutical Technology, 2009, (4 pages). [cited by applicant]
Cherng, Yie-Jia , “Synthesis of substituted pyridines by the reactions of halopyridines with sulfur, oxygen and carbon nucleophiles under focused microwave irradiation”, Tetrahedron, vol. 58, No. 24, Jun. 10, 2002, pp. … [cited by applicant]
Costello, Leslie C., et al., “Evidence for Changes in RREB-1, ZIP3, and Zinc in the Early Development of Pancreatic Adenocarcinoma”, Journal of Gastrointestinal Cancer, vol. 43, No. 4, 2012, pp. 570-578, DOI: 10.1007/s1… [cited by applicant]
Cousins, Scott W., “Intravitreal Anti-VEGF and Anti-PDGF Combination Therapy”, Retina Today, Oct. 2009, Retrieved from URL: http://retinatoday.com/2009/10/1009_12.php, (2 pages). [cited by applicant]
Cunliffe, C. Jane , et al., “Novel inhibitors of prolyl 4-hydroxylase. 3. Inhibition by the substrate analog N-oxaloglycine and its derivatives”, Journal of Medicinal Chemistry, vol. 35, No. 14, 1992, pp. 2652-2658, DOI… [cited by applicant]
Demetriades, Marina , et al., “Dynamic Combinatorial Chemistry Employing Boronic Acids/Boronate Esters Leads to Potent Oxygenase Inhibitors”, Angewandte Chemie, International Edition , vol. 51, No. 27, Jul. 2, 2012,pp. … [cited by applicant]
Dranoff, Glenn , “GM-CSF-secreting melanoma vaccines”, Oncogene, vol. 22, 2003, pp. 3188-3192, DOI: 10.1038/sj.onc.1206459, (5 pages). [cited by applicant]
Elson, David A., et al., “Induction of hypervascularity without leakage or inflammation in transgenic mice overexpressing hypoxia-inducible factor-1α”, Genes & Development, vol. 15, 2001, pp. 2520-2532, DOI: 10.1101/gad… [cited by applicant]
Elvidge, Gareth P., et al., “Concordant Regulation of Gene Expression by Hypoxia and 2-Oxoglutarate-dependent Dioxygenase Inhibition”, Journal of Biological Chemistry, vol. 281, No. 22, Jun. 2006, pp. 15215-15226, DOI: … [cited by applicant]
Enoch, Stuart , et al., “ABC of wound healing: Non-surgical and drug treatments”, BMJ, vol. 332, No. 7546, 2006, pp. 900-903, DOI: 10.1074/jbc.M511408200, (4 pages). [cited by applicant]
Favier, Judith , et al., “HIF2α reduces growth rate but promotes angiogenesis in a mouse model of neuroblastoma”, BMC Cancer, vol. 7, Article No. 139, 2007, DOI: 10.1186/1471-2407-7-139, (10 pages). [cited by applicant]
Flower, Darren R, et al., “Modelling G-protein-coupled receptors for drug design”, Biochimica et Biophysica Acta (BBA)—Reviews on Biomembranes, vol. 1422, No. 3, Nov. 16, 1999, pp. 207-234, DOI: 10.1016/s0304-4157(99)00… [cited by applicant]
Folkman, Judah , “Chapter 10—Tumor Angiogenesis”, The Molecular Basis of Cancer, 1995, pp. 206-232, (29 pages). [cited by applicant]
Franklin, Trevor J, et al., “Approaches to the design of anti-fibrotic drugs”, Biochemical Society Transactions, vol. 19, No. 4, Nov. 1991, pp. 812-815, DOI: 10.1042/bst0190812, (4 pages). [cited by applicant]
Gaunt, Matthew J, et al., “Rational Design of Benzyl-Type Protecting Groups Allows Sequential Deprotection of Hydroxyl Groups by Catalytic Hydrogenolysis”, Journal of Organic Chemistry, vol. 63, No. 13, 1998, pp. 4172-4… [cited by applicant]
Gaunt, Matthew J, et al., “Rational Design of Benzyl-Type Protecting Groups Allows Sequential Deprotection of Hydroxyl Groups by Catalytic Hydrogenolysis”, Journal of Organic Chemistry, vol. 63, No. 13, 1998, pp. 4172-4… [cited by applicant]
Gavhane, Y. N. , et al., “Solid Tumors: Facts, Challenges and Solutions”, International Journal of Pharma Sciences and Research, vol. 2, No. 1, 2011, pp. 1-12, (12 pages). [cited by applicant]
Goodford, P. J. , et al., “A computational procedure for determining energetically favorable binding sites on biologically important macromolecules”, Journal of Medicinal Chemistry, vol. 28, No. 7, 1985, pp. 849-857, DO… [cited by applicant]
Goodsell, David S., et al., “Automated docking of substrates to proteins by simulated annealing”, Proteins, vol. 8, No. 3, 1990, pp. 195-202, DOI: 10.1002/prot.340080302, (8 pages). [cited by applicant]
Greer, Samantha N, et al., “The updated biology of hypoxia-inducible factor”, The EMBO Journal, vol. 31, No. 11, May 30, 2012, pp. 2448-2460, DOI: 10.1038/emboj.2012.125, (13 pages). [cited by applicant]
Hardcastle, Ian R., et al., “Discovery of Potent Chromen-4-one Inhibitors of the DNA-Dependent Protein Kinase (DNA-PK) Using a Small-Molecule Library Approach”, Journal of Medicinal Chemistry, vol. 48, No. 24, 2005, pp.… [cited by applicant]
Hoeksema, H. , et al., “Structure of rubradirin”, Journal of the American Chemical Society, vol. 104, No. 19, 1982, pp. 5173-5181, DOI: 10.1021/ja00383a030, (9 pages). [cited by applicant]
Hu, Cheng-Jun , et al., “Differential Roles of Hypoxia-Inducible Factor 1α (HIF-1α) and HIF-2α in Hypoxic Gene Regulation”, Molecular and Cellular Biology, vol. 23, No. 24, 2003, pp. 9361-9374, DOI: 10.1128/MCB.23.24.93… [cited by applicant]
Ingersoll, A. W. , et al., “Hippuric Acid”, Organic Synthesis, CV 2, 328, Retrieved on Mar. 11, 2010 from the Internet at <http://web.archive.org/web/20020724135719/http://www.orgsyn.org/orgsyn/orgsyn/prepContent.asp?pr… [cited by applicant]
Ivan, Mircea , et al., “Biochemical purification and pharmacological inhibition of a mammalian prolyl hydroxylase acting on hypoxia-inducible factor”, PNAS, vol. 99, No. 21, Sep. 26, 2002, pp. 13459-13464, DOI: 10.1073/… [cited by applicant]
Ivan, Mircea , et al., “HIFα Targeted for VHL-Mediated Destruction by Proline Hydroxylation: Implications for O2 Sensing”, Science, vol. 292, No. 5516, Apr. 5, 2001, pp. 464-468, DOI: 10.1126/science.1059817, (5 pages). [cited by applicant]
Ivanisevic, Igor , et al., “Uses of X-Ray Powder Diffraction In the Pharmaceutical Industry”, Pharmaceutical Formulation and Quality, 2010, DOI: 10.1002/9780470571224.pse414, (4 pages). [cited by applicant]
Iyoda, Masahiko , et al., “Homocoupling of Aryl Halides Using Nickel(II) Complex and Zinc in the Presence of Et4NI. An Efficient Method for the Synthesis of Biaryls and Bipyridines”, Bulletin of the Chemical Society of … [cited by applicant]
Jaakkola, Panu , et al., “Targeting of HIF-α to the von Hippel-Lindau Ubiquitylation Complex by O2-Regulated Prolyl Hydroxylation”, Science, vol. 292, No. 5516, Apr. 5, 2001, pp. 468-472, DOI: 10.1126/science.1059796, (… [cited by applicant]
Jones, Gareth , et al., “Molecular recognition of receptor sites using a genetic algorithm with a description of desolvation”, Journal of Molecular Biology, vol. 245, No. 1, 1995, pp. 43-53, DOI: 10.1016/s0022-2836(95)8… [cited by applicant]
Kaelin, William G., “Proline hydroxylation and gene expression”, Annual Review of Biochemistry, vol. 74, 2005, pp. 115-128, DOI: 10.1146/annurev.biochem.74.082803.133142, (14 pages). [cited by applicant]
Karuppagounder, Saravanan S, et al., “Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibition: Robust New Target or Another Big Bust for Stroke Therapeutics?”, Journal of Cerebral Blood Flow & Metabolism, vol. 32, No. 7,… [cited by applicant]
Kawashima, Yoichiro , et al., “Suppressive Effect of Quinolinic Acid and Hippuric Acid on Bone Marrow Erythroid Growth and Lymphocyte Blast Formation in Uremia”, Advances in Experimental Medicine and Biology, vol. 223, … [cited by applicant]
Ke, Qingdong , et al., “Hypoxia-Inducible Factor-1 (HIF-1)”, Molecular Pharmacology, vol. 70, No. 5, Nov. 2006, pp. 1469-1480, DOI: 10.1124/mol.106.027029, (12 pages). [cited by applicant]
Khandhadia, Sam , et al., “Age-Related Macular Degeneration”, Neurodegenerative Diseases, Landes Bioscience and Springer Science+Business Media, 2012, pp. 15-36, (22 pages). [cited by applicant]
Kietzmann, Thomas , et al., “Perivenous expression of the mRNA of the three hypoxia-inducible factor α-subunits, HIF1α, HIF2α and HIF3α, in rat liver”, Biochemical Journal, vol. 354, No. 3, Mar. 2001, pp. 531-537, DOI: … [cited by applicant]
Kim, so Yeon , et al., “Recent Advances in Developing Inhibitors for Hypoxia-Inducible Factor Prolyl Hydroxylases and Their Therapeutic Implications”, Molecules, vol. 20, No. 11, 2015, pp. 20551-20568, DOI: 10.3390/mole… [cited by applicant]
Kirwan, D.J. , et al., “11-Crystallization in the pharmaceutical and bioprocessing industries”, Handbook of Industrial Crystallization (Second Edition), 2002, pp. 249-266, DOI: 10.1016/B978-075067012-8/50013-6, (20 page… [cited by applicant]
Krantz, Sanford B, “Erythropoietin”, Blood, vol. 77, No. 3, Feb. 1, 1991, pp. 419-434, DOI: 10.1182/blood.V77.3.419.419, (16 pages). [cited by applicant]
Kuntz, Irwin D., et al., “A geometric approach to macromolecule-ligand interactions”, Journal of Molecular Biology, vol. 161, No. 2, Oct. 25, 1982, pp. 269-288, DOI: 10.1016/0022-2836(82)90153-x, (20 pages). [cited by applicant]
Kurti, Laszlo , et al., “Strategic Applications of Named Reactions in Organic Synthesis”, Elsevier, 2005, pp. 448-449, (4 pages). [cited by applicant]
Langsetmo, Ingrid , et al., “Inhibition of HIF-Prolyl Hydroxylases with FG-4539 IS Neuroprotective in a Mouse Model of Permanent Focal Ischemia”, International Stroke Conference, Kissimmee, Florida, Presentation No. 427… [cited by applicant]
Lee, Cheolju , et al., “Structure of Human FIH-1 Reveals a Unique Active Site Pocket and Interaction Sites for HIF-1 and von Hippel-Lindau”, Enzyme Catalysis and Regulation, vol. 278, No. 9, Feb. 2003, pp. 7558-7563, DO… [cited by applicant]
Li, Jian , et al., “PR39, a peptide regulator of angiogenesis”, Nature Medicine, vol. 6, No. 1, 2000, pp. 49-55, DOI: 10.1038/71527, (7 pages). [cited by applicant]
Lima, Lidia Moreira, et al., “Bioisosterism: A Useful Strategy for Molecular Modification and Drug Design”, Current Medicinal Chemistry, vol. 12, No. 1, 2005, pp. 23-49, DOI: 10.2174/0929867053363540, (27 pages). [cited by applicant]
Liu, Quanyan , et al., “Hypoxia induces genomic DNA demethylation through the activation of HIF-1α and transcriptional upregulation of MAT2A in hepatoma cells”, Molecular Cancer Therapeutics, vol. 10, No. 6, Jun. 1, 201… [cited by applicant]
Mancini, Donna M, et al., “Effect of Erythropoietin on Exercise Capacity in Patients With Moderate to Severe Chronic Heart Failure”, Circulation, vol. 107, No. 2, 2002, pp. 294-299, DOI: 10.1161/01.CIR.0000044914.42696.… [cited by applicant]
McDonough, Michael A., et al., “Cellular oxygen sensing: Crystal structure of hypoxia-inducible factor prolyl hydroxylase (PHD2)”, PNAS, vol. 103, No. 26, Jun. 27, 2006, pp. 9814-9819, DOI: 10.1073/pnas.0601283103, (6 p… [cited by applicant]
Miranker, Andrew , et al., “Functionality maps of binding sites: A multiple copy simultaneous search method”, Proteins: Structure, Function and Genetics, vol. 11, No. 1, Sep. 1991, pp. 29-34, DOI: 10.1002/prot.340110104… [cited by applicant]
Morissette, Sherry L., et al., “High-throughput crystallization: polymorphs, salts, co- crystals and solvates of pharmaceutical solids”, Advanced Drug Delivery Reviews, vol. 56, No. 3, Feb. 23, 2004, pp. 275-300, DOI: 1… [cited by applicant]
Moss, G.P. , et al., “Glossary of class names of organic compounds and reactivity intermediates based on structure (IUPAC Recommendations 1995”, Pure and Applied Chemistry, vol. 67, Nos. 8/9, 1995, pp. 1307-1375, DOI: 1… [cited by applicant]
Nguyen, Louis L., et al., “Cellular interactions in vascular growth and differentiation”, International Review of Cytology, vol. 204, 2001, pp. 1-48, DOI: 10.1016/s0074-7696(01)04002-5, (48 pages). [cited by applicant]
Nielsen, Dorte Lisbet, “Antiangiogenic therapy for breast cancer”, Breast Cancer Research, vol. 12, Article No. 209, 2010, DOI: 10.1186/bcr2642, (16 pages). [cited by applicant]
Nishibata, Yoshihiko , et al., “Automatic creation of drug candidate structures based on receptor structure. Starting point for artificial lead generation.”, Tetrahedron, vol. 47, No. 43, Nov. 4, 1991, pp. 8985-8990, DO… [cited by applicant]
Nowak, Jerzy Z, “Age-related macular degeneration (AMD): pathogenesis and therapy”, Pharmacological Reports, vol. 58, 2006, pp. 353-363, (11 pages). [cited by applicant]
O'Reilly, Michael S., et al., “Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a lewis lung carcinoma”, Cell, vol. 79, No. 2, 1994, pp. 315-328, DOI: 10.1016/0092-8674(94)90200… [cited by applicant]
O'reilly, Michael S., “Endostatin: An Endogenous Inhibitor of Angiogenesis and Tumor Growth”, Cell, vol. 88, No. 2, 1997, pp. 277-285, DOI: 10.1016/S0092-8674(00)81848-6, (9 pages). [cited by applicant]
Pasqualetti, P. , et al., “Circadian rhythm of serum erythropoietin in myelodysplastic syndromes”, European Review for Medical and Pharmacological Sciences, vol. 4, 2000, pp. 111-115 (5 pages). [cited by applicant]
Pergola, Pablo E., et al., “Vadadustat, a novel oral HIF stabilizer, provides effective anemia treatment in nondialysis-dependent chronic kidney disease”, Kidney International, vol. 90, No. 5, Nov. 2016, pp. 1115-1122, … [cited by applicant]
Peyssonnaux, Carole , et al., “HIF-1α expression regulates the bactericidal capacity of phagocytes”, The Journal of Clinical Investigation, vol. 115, No. 7, Jul. 2005, pp. 1806-1815, DOI: 10.1172/JCI23865, (10 pages). [cited by applicant]
Piyamongkol, Sirivipa , et al., “Amido-3-hydroxypyridin-4-ones as Iron(III) Ligands”, Chemistry A European Journal, vol. 16, No. 21, Jun. 1, 2010, pp. 6374-6381, DOI: 10.1002/chem.200902455, (8 pages). [cited by applicant]
Piyamongkol, Sirivipa , et al., “Amido-3-hydroxypyridin-4-ones as Iron(III) Ligands”, Chemistry A European Journal, vol. 16, No. 21, Jun. 1, 2010, pp. 6374-6381, DOI: 10.1002/chem.200902455, Supporting Information (53 p… [cited by applicant]
Prabhakar, Nanduri R., et al., “Adaptive and Maladaptive Cardiorespiratory Responses to Continuous and Intermittent Hypoxia Mediated by Hypoxia-Inducible Factors 1 and 2”, Physiological Reviews, vol. 92, No. 3, Jul. 201… [cited by applicant]
Qian, Jia Qi, et al., “A Randomized, Double-Bind, Placebo Controlled Trial FG-4592 for Correction of Anemia in Subjects with Chronic Kidney Disease in China”, Journal of the American Society of Nephrology, vol. 24, 2013… [cited by applicant]
Qunibi, Wajeh Y., et al., “A randomized controlled trial comparing intravenous ferric carboxymaltose with oral iron for treatment of iron deficiency anaemia of non-dialysis-dependent chronic kidney disease patients”, Ne… [cited by applicant]
Rahtu-Korpela, Lea , et al., “HIF Prolyl 4-Hydroxylase-2 Inhibition Improves Glucose and Lipid Metabolism and Protects Against Obesity and Metabolic Dysfunction”, Diabetes, vol. 63, No. 10, 2014, pp. 3324-3333, DOI: 10.… [cited by applicant]
Rankin, Erinn B., et al., “Hypoxia-inducible factor-2 (HIF-2) regulates hepatic erythropoietin in vivo”, The Journal of Clinical Investigation, vol. 117, No. 4, Apr. 2007, pp. 1068-1077, DOI: 10.1172/JCI30117, (10 pages… [cited by applicant]
Ratcliffe, Peter J., “HIF-1 and HIF-2: working alone or together in hypoxia?”, The Journal of Clinical Investigation, vol. 117, No. 4, Apr. 2007, 862-865, DOI: 10.1172/JCI31750, (4 pages). [cited by applicant]
Redondo, Pedro , et al., “Vascular endothelial growth factor (VEGF) and melanoma. N-acetylcysteine downregulates VEGF production in vitro”, Cytokine, vol. 12, No. 4, Apr. 2000, pp. 374-378, DOI: 10.1006/cyto.1999.0566, … [cited by applicant]
Roda, Julie M., et al., “Stabilization of HIF-2α Induces sVEGFR-1 Production from Tumor-Associated Macrophages and Decreases Tumor Growth in a Murine Melanoma Model”, The Journal of Immunology, vol. 189, No. 6, Sep. 15,… [cited by applicant]
Schelhaas, Michael , et al., “Protecting Group Strategies in Organic Synthesis”, Angewandte Chemie, International Edition, vol. 35, No. 18, Oct. 1, 1996, pp. 2056-2083, DOI: 10.1002/anie.199620561, (27 pages). [cited by applicant]
Schöneberg, Torsten , et al., “Structural basis of G protein-coupled receptor function”, Molecular and Cellular Endocrinology, vol. 151, No. 1-2, May 25, 1999, pp. 181-193, 10.1016/S0303-7207(99)00017-9, (13 pages). [cited by applicant]
Semenza, Gregg L, “Regulation of Erythropoiesis by the Hypoxia-Inducible Factor Pathway: Effects of Genetic and Pharmacological Perturbations”, Hematology/Oncology Clinic of North America, vol. 8, No. 5, Oct. 1994, pp. … [cited by applicant]
Semenza, Gregg L., et al., “HIF-1 and human disease: one highly involved factor”, Genes & Development, vol. 14, No. 16, 2000, pp. 1983-1991, DOI: 10.1101/gad.14.16.1983, (10 pages). [cited by applicant]
Semenza, Gregg L., et al., “Signal transduction to hypoxia-inducible factor 1”, Biochemical Pharmacology, vol. 64, No. 5-6, Sep. 2002, pp. 993-998, DOI: 10.1016/s0006-2952(02)01168-1, (6 pages). [cited by applicant]
Semenza, Gregg L., et al., “Transcriptional regulation of genes encoding glycolytic enzymes by hypoxia-inducible factor 1”, The Journal of Biological Chemistry, vol. 269, No. 38, Sep. 23, 1994, pp. 23757-23763, (7 pages… [cited by applicant]
Sexton, Patrick M, et al., “Recent advances in our understanding of peptide hormone receptors and RAMPS”, Current Opinions in Drug Discovery & Development, vol. 2, No. 5, 1999, pp. 440-448, (9 pages). [cited by applicant]
Sheehan, John T, “3-Hydroxypicolinic Acid and Some of Its Derivatives”, The Journal of Organic Chemistry, vol. 31, No. 2, 1966, pp. 636-638, DOI; 10.1021/jo01340a533, (5 pages). [cited by applicant]
Siddiq, Ambreena , et al., “Hypoxia-inducible Factor Prolyl 4-Hydroxylase Inhibition. A target for neuroprotection in the central nervous system”, Journal of Biological Chemistry, vol. 280, No. 50, Dec. 2005, pp. 41732-… [cited by applicant]
Sowter, Heidi M., et al., “Predominant Role of Hypoxia-Inducible Transcription Factor (Hif)-1α versus Hif-2α in Regulation of the Transcriptional Response to Hypoxia”, Cancer Research, vol. 63, No. 19, Oct. 1, 2003, pp.… [cited by applicant]
Sporn, Michael B., et al., “Chemoprevention of cancer”, Carcinogenesis, vol. 21, No. 3, Mar. 2000, pp. 525-530, DOI: 10.1093/carcin/21.3.525, (6 pages). [cited by applicant]
Stille, John K., et al., “The Palladium-Catalyzed Cross-Coupling Reactions of Organotin Reagents with Organic Electrophiles”, Angewandte Chemie, International Edition, vol. 25, No. 6, Jun. 1986, pp. 508-524, DOI: 10.100… [cited by applicant]
Stohlawetz, Petra Jilma, et al., “Effects of erythropoietin on platelet reactivity and thrombopoiesis in humans”, Blood, vol. 95, No. 9, May 1, 2000, pp. 2983-2989 (7 pages). [cited by applicant]
Sutter, Carrie Hayes, et al., “Hypoxia-inducible factor 1α protein expression is controlled by oxygen-regulated ubiquitination that is disrupted by deletions and missense mutations”, PNAS, vol. 97, No. 9, Apr. 11, 2000,… [cited by applicant]
Teicher, Beverly A., et al., “Potentiation of cytotoxic cancer therapies by TNP-470 alone and with other anti-angiogenic agents”, International Journal of Cancer, vol. 57, No. 6, Jun. 15, 1994, pp. 920-925, DOI: 10.1002… [cited by applicant]
Thoppil, Roslin J, et al., “Terpenoids as potential chemopreventive and therapeutic agents in liver cancer”, World Journal of Hepatology, vol. 3, No. 9, 2011, pp. 228-249, DOI: 10.4254/wjh.v3.i9.228, (22 pages). [cited by applicant]
Thornber, C. W. , et al., “Isosterism and molecular modification in drug design”, Chemical Society Reviews, No. 8, 1979, 563-580, DOI: 10.1039/CS9790800563, (18 pages). [cited by applicant]
Tzschucke, Carl Christoph, et al., “Fluorous-Silica-Supported Perfluoro-Tagged Palladium Complexes Catalyze Suzuki Couplings in Water”, Helvetica Chima Acta, vol. 87, No. 11, Nov. 2004, pp. 2882-2889, DOI: 10.1002/hlca.… [cited by applicant]
Ullman, F. , et al., “Ueber Synthesen in der Biphenyireihe”, Ber. Deutsch. Chem. Ges., 1901, pp. 2174, (12 pages). [cited by applicant]
Variankaval, Narayan , et al., “From form to function: Crystallization of active pharmaceutical ingredients”, AlChE Journal, vol. 54, No. 7, Jul. 2008, pp. 1682-1688, DOI: 10.1002/aic.11555, (7 pages). [cited by applicant]
Vickerstaffe, Emma , et al., “Fully Automated Polymer-Assisted Synthesis of 1,5-Biaryl Pyrazoles”, Journal of Combinatorial Chemistry, vol. 6, 2004, pp. 332-339, DOI: 10.1021/cc049977g, (8 pages). [cited by applicant]
Vincent, Karen A., et al., “Angiogenesis Is Induced in a Rabbit Model of Hindlimb Ischemia by Naked DNA Encoding an HIF-1α/VP16 Hybrid Transcription Factor”, Circulation, vol. 102, No. 18, Oct. 31, 2000, pp. 2255-2261, … [cited by applicant]
Vippagunta, Sudha R., et al., “Crystalline solids”, Advanced Drug Delivery Reviews, vol. 48, No. 1, May 16, 2001, pp. 3-26, DOI: 10.1016/S0169-409X(01)00097-7, (23 pages). [cited by applicant]
Wade, L. G. , et al., “Organic Chemistry”, Wade et al., Organic Chemistry, Sixth Edition, 2005, pp. 780-781, (5 pages). [cited by applicant]
Warnecke, Christina , et al., “Activation of the hypoxia-inducible factor-pathway and stimulation of angiogenesis by application of prolyl hydroxylase inhibitors”, The FASEB Journal, vol. 17, No. 9, 2003, pp. 1186-1188,… [cited by applicant]
Warshakoon, Namal C., et al., “Design and synthesis of substituted pyridine derivatives as HIF-1α prolyl hydroxylase inhibitors”, Bioorganic & Medicinal Chemistry Letters, vol. 16, No. 21, Nov. 1, 2006, pp. 5616-5620, D… [cited by applicant]
Wax, Stephen D., et al., “SM-20 is a novel 40-kd protein whose expression in the arterial wall is restricted to smooth muscle”, Laboratory Investigation, vol. 74, No. 4, 1996, pp. 797-808, (12 pages). [cited by applicant]
Weidner, Noel , et al., “Tumor Angiogenesis and Metastasis—Correlation in Invasive Breast Carcinoma”, The New England Journal of Medicine, vol. 324, No. 1, pp. 1-8, DOI: 10.1056/NEJM199101033240101, (111 pages). [cited by applicant]
Wiesener, Michael S., et al., “Widespread hypoxia-inducible expression of HIF-2alpha in distinct cell populations of different organs”, The FASEB Journal, vol. 17, No. 2, 2003, pp. 271-273, DOI: 10.1096/fj.02-0445fje, (… [cited by applicant]
Wright, Gary , et al., “Activation of the Prolyl Hydroxylase Oxygen-sensor Results in Induction of GLUT1, Heme Oxygenase-1, and Nitric-oxide Synthase Proteins and Confers Protection from Metabolic Inhibition to Cardiomy… [cited by applicant]
Wu, Florence T.H., et al., “A systems biology perspective on sVEGFR1: its biological function, pathogenic role and therapeutic use”, Journal of Cellular and Molecular Medicine, vol. 14, No. 3, Apr. 21, 2010, pp. 528-552… [cited by applicant]
Yang, Linlin , et al., “Desmoplakin acts as a tumor suppressor by inhibition of the Wnt/β-catenin signaling pathway in human lung cancer”, Carcinogenesis, vol. 33, No. 10, Oct. 2012, pp. 1863-1870, DOI: 10.1093/carcin/b… [cited by applicant]